早期淋巴细胞恢复预示着急性髓系白血病非处理单倍体相合造血干细胞移植后有更好的预后。
Early lymphocyte recovery predicts superior outcomes after unmanipulated haploidentical blood and marrow transplant for acute myeloid leukemia.
作者信息
Fu Qiang, Xu Lan-Ping, Zhang Xiao-Hui, Wang Yu, Chang Ying-Jun, Huang Xiao-Jun
机构信息
Beijing Key Laboratory of HSCT, Peking University People's Hospital & Peking University Institute of Hematology, Beijing, China.
Peking-Tsinghua Center for Life Sciences, Beijing, China.
出版信息
Clin Transplant. 2016 Aug;30(8):954-8. doi: 10.1111/ctr.12771. Epub 2016 Jun 27.
We investigated whether early lymphocyte recovery, after unmanipulated haploidentical blood and marrow transplant (HBMT), affected clinical outcomes in 134 patients with acute myeloid leukemia (AML). Lymphocyte recovery was based on the absolute lymphocyte count on day 30 (ALC-30). Patients with high ALC-30 (≥294 cells/μL) had higher overall survival (OS) (77.6% vs 59.7%, P=.020) and higher leukemia-free survival (LFS) (74.6% vs 53.7%, P=.016) than those with low ALC-30 values. Multivariate analysis demonstrated that a high ALC-30 was associated with improved overall survival (HR: 0.443, 95% CI: 0.233-0.841; P=.013) and LFS (HR: 0.499, 95% CI: 0.275-0.906; P=.022). Our results suggest that the ALC-30 can predict a superior outcome after unmanipulated HBMT.
我们调查了134例急性髓系白血病（AML）患者在未处理的单倍体相合造血干细胞移植（HBMT）后早期淋巴细胞恢复情况是否会影响临床结局。淋巴细胞恢复情况基于第30天的绝对淋巴细胞计数（ALC-30）。与ALC-30值低的患者相比，ALC-30高（≥294个细胞/μL）的患者总生存期（OS）更高（77.6%对59.7%，P = 0.020），无白血病生存期（LFS）也更高（74.6%对53.7%，P = 0.016）。多因素分析表明，高ALC-30与改善的总生存期（HR：0.443，95%CI：0.233 - 0.841；P = 0.013）和LFS（HR：0.499，95%CI：0.275 - 0.906；P = 0.022）相关。我们的结果表明，ALC-30可预测未处理的HBMT后的较好结局。
Zotero 插件